Skip to main content

Advertisement

Table 4 Cost-effectiveness of different types of pneumococcal conjugate vaccines (PCVs)

From: Economic evaluation of pneumococcal conjugate vaccination in The Gambia

Outcomes No vaccination Vaccination
(PCV7)
Vaccination (PCV10) Vaccination (PCV13)
K = 0 (base-case)     
Cost (2005 US$) 233,100 906,240 902,040 899,280
Incremental cost (2005 US$) - 673,140 668,940 666,180
Effectiveness (DALYs) 182,630 181,890 181,630 181,450
Incremental effectiveness (DALYs averted) - 740 1,000 1,180
ICER (2005 US$/DALY averted) - 910 670 570
ICER expressed as % per capita GDPa   250% 190% 160%
K = 1     
Cost (2005 US$) 233,100 906,240 902,040 899,280
Incremental cost (2005 US$) - 673,140 668,940 666,180
Effectiveness (DALYs) 208,670 207,820 207,530 207,330
Incremental effectiveness (DALYs averted) - 850 1,140 1,340
ICER (2005 US$/DALY averted) - 800 590 500
ICER expressed as % per capita GDPa   220% 160% 140%
  1. DALY: disability-adjusted life year, K = 0: uniform age-weights used in DALY calculation, K = 1: non-uniform age-weights used in DALY calculation, ICER: incremental cost-effectiveness ratio.
  2. a $360 (in 2005 US$) in The Gambia for 2008.